Research conducted by CPhI Worldwide, drawing from the CPhI Annual Report, ranks Germany as Europe’s preeminent pharma industry.
According to the report’s Pharma Index, Germany finished ahead of its European rivals in API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential, thus “consolidating its status as an elite pharmaceutical market.”
One of the most notable trends, the report states, is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a “Brexit boost” in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.
The full CPhI Pharma Market Index will be available later in the year as part of the CPhI 2019 Industry Report. This year’s CPhI Worldwide event will be held at Messe Frankfurt, Germany, November 5-7, 2019.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.